1.Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O’Brien KL. Estimating the Burden of Pneumococcal Pneumonia among Adults: A Systematic Review and Meta-Analysis of Diagnostic Techniques. PloS one. 2013;8(4):e60273.
2.Song JH, Oh WS, Kang CI, Chung DR, Peck KR, Ko KS et al. Epidemiology and clinical outcomes of community-acquired pneumonia in adult patients in Asian countries: a prospective study by the Asian network for surveillance of resistant pathogens. Int J Antimicrob Ag. 2008;31:107–114.
3.Drijkoningen JJC, Rohde GGU. Pneumococcal infection in adults: burden of disease. Clin Microbio Infect. 2014;20(Suppl. 5):45–51.
4.Low S, Chan FLF, Cutter J, Ma S, Goh KT, Chew SK. A national study of the epidemiology of pneumococcal disease among hospitalised patients in Singapore: 1995–2004. Singap Med J. 2007;48(9):824–829.
5.Jackson ML, Neuzil KM, Thompson WW, Shay DK, Yu O, Hanson CA et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2004;39(11):1642–1650.
6.Hsu LY, Lui SW, Lee JL, Hedzlyn HM, Kong DH, Shameen S et al. Adult invasive pneumococcal disease pre- and peri- pneumococcal conjugate vaccine introduction in a tertiary hospital in Singapore. J Med Microbiol. 2009;58(Pt 1):101–104.
7.Bogaert D, de Groot R, Hermans PWM. Streptococcus pneumoniae colonisation: the key to pneumococcal disease. The Lancet. Infectious diseases. 2004;4:144–154.
8.Lynch 3rd JP, Zhanel GG. Streptococcus pneumoniae: epidemiology, risk factors, and strategies for prevention. Semin Respir Crit Care Med. 2009;30(2):189–209.
9.TM F. Streptococcus pneumoniae and community-acquired pneumonia: a cause for concern. Am J Med. 2004;117 (Suppl 3A):39S–50S.
10.Vasoo S, Singh K, Chow C, Tzer RPL, Hsu LY, Tambayah PA. Pneumococcal carriage and resistance in children attending day care centres in Singapore in an early era of PCV–7 uptake. J Infection 2010;60(June 6):507–509.
11.Pletz MW, Rohde GG, Welte T, Kolditz M, Ott S. Advances in the prevention, management, and treatment of community-acquired pneumonia. F1000Res. 2016;5:F1000 Faculty Rev–1300.
12.Eng P, Lim LH, Loo CM, Low JA, Tan C, Tan EK et al. Role of pneumococcal vaccination in prevention of pneumococcal disease among adults in Singapore. Int J Gen Med. 2014;7:179–191.
13.Falkenhorst G, Remschmidt C, Harder T, Hummers-Pradier E2, Wichmann O, Bogdan C. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis. PloS one. 2017;12(1):e0169368.
14.Bonten MJ, Huijts SM, Bolkenbaas M, Webber C. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med . 2015;372(12):1114–1125.
15.Golos M, Eliakim-Raz N, Stern A, Leibovici L, Paul M. Conjugated pneumococcal vaccine versus polysaccharide pneumococcal vaccine for prevention of pneumonia and invasive pneumococcal disease in immunocompetent and immunocompromised adults and children. John Wiley & Sons, Ltd; 2016.https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012306/full. Accessed 27 September 2018.
16.Tomczyk S, Bennett NM, Stoecker C, aGierke R, Moore MR, Whitney CG et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014;63(37):822–825.
17.MOH. National Immunisation Schedule 2017 https://www.moh.gov.sg/content/moh_web/home/pressRoom/pressRoomItemRelease/2017/moh-establishes-national-adult-immunisation-schedule—extends-us.html. Accessed 9 May 2018, 2018
18.Ho HJ, Chan YY, Ibrahim MAB, Wagie AA, Wong CM, Chow A. A formative research-guided educational intervention to improve the knowledge and attitudes of seniors towards influenza and pneumococcal vaccinations. Vaccine. 2017;7(35(47)):6367–6374.
19.Bravo LC, Asian Strategic Alliance for Pneumococcal Disease Prevention (ASAP) Working Group. Overview of the disease burden of invasive pneumococcal disease in Asia. Vaccine. 2009;27(52):7282–7291.
20.Hung IF, Tantawichien T, Tsai YH, Patil S, Zotomayor R. Regional epidemiology of invasive pneumococcal disease in Asian adults: epidemiology, disease burden, serotype distribution, and antimicrobial resistance patterns and prevention. Int J Infect Dis. 2013;17(6):e364–373.
21.Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Jean-Christophe L et al. Coding algorithms for defining comorbidities in ICM–9-CM and ICD–10 administrative data. Med Care.43(11):1130–1139.
22.Ministry of Trade and Industry: Department of Statistics. Population Trends. 2017; https://www.singstat.gov.sg/-/media/files/publications/population/population2017.pdf. Accessed 26th September 2018, 2018.
23.Fung HB, Monteagudo-Chu MO. Community- Acquired Pneumonia in the Elderly. Am J Geriatr Pharmac. 2010;8(1):47–62.
24.Weinberger B, Herndler-Brandstetter D, Schwanninger A, Weiskopf D, Grubeck-Loebenstein B. Biology of immune responses to vaccines in elderly persons. Vaccine. 2008;46:1078–1084.
25.Gavazzi G, Krause K-H. Ageing and infection. The Lancet. Infectious diseases. 2002;2(11):659–666.
26.Yoshikawa TT. Epidemiology and unique aspects of aging and infectious diseases. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2000;30(6):931–933.
27.Jauneikaite E, Jefferies JMC, Churton NWV, Tzer RPL, Hibberd ML, Clarke SC. Genetic diversity of Streptococcus pneumonia causing meningitis and sepsis in Singapore during the first year of PCV7 implementation. Emerg Microbes infect. 2014;3:e39.
28.Imai K, Petigara T, Kohn MA, Nakashima K, Aoshima M, Shito A et al. Risk of pneumococcal diseases in adults with underlying medical conditions: a retrospective, cohort study using two Japanese healthcare databases. BMJ Open. 2018;8(3):e018553.
29.Marrie TJ, Tyrrell GJ, Sumit RM, Eurcih DT. Effect of age on the manifestations and outcomes of invasive pneumococcal disease in adults. Am J Med. 2018;131(1):100.e101–100.e107.
30.Flasche S, Van Hoek AJ, Goldblatt D, Edmunds WJ, O’Brien KL, Scott JA et al. The Potential for Reducing the Number of Pneumococcal Conjugate Vaccine Doses While Sustaining Herd Immunity in High-Income Countries. PLoS Med. 2015;12(6):e1001839.
31.McIntosh ED, Conway P, Willingham J, Hollingsworth R, Llyod A. Pneumococcal pneumonia in the UK—how herd immunity affects the cost-effectiveness of 7-valent pneumococcal conjugate vaccine (PCV). Vaccine. 2005;23(14):1739–1745.
32.Pletz MW, Maus U, Hohlfeld JM, Lode H, Welte T. Pneumococcal vaccination: conjugated vaccine induces herd immunity and reduces antibiotic resistance. Dtsch Med Wochenschr. 2008;133(8):358–362.
33.Stephens DS. Protecting the Herd: The Remarkable Effectiveness of the Bacterial Meningitis Polysaccharide-Protein Conjugate Vaccines in Altering Transmission Dynamics. Trans Am Clin Climatol Assoc. 2011;122:115–123.
34.Ministry of Health, Singapore. Medisave for Chronic Disease Management Programme (CDMP) and vaccinations. https://www.moh.gov.sg/content/moh_web/home/policies-and-issues/elderly_healthcare.html Accessed 9 May 2018, 2018.
35.Tyo KR, Rosen MM, Zeng W. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines. Vaccine. 2011;29(38):6686–6694.
36.Sinclair A, Xie X, Teltscher M, Dendukuri N. Systematic review and meta-analysis of a urine-based pneumococcal antigen test for diagnosis of community-acquired pneumonia caused by Streptococcus pneumoniae. J Clin Microbiol. 2013;51(7):2303–2310.